Guerbet will be unveiling new data on Elucirem (Gadopiclenol), said to be the first half-dose gadolinium-based contrast agent now approved in Great Britain.
Delivering high quality images at half the conventional dose, Elucirem is indicated for adults and children aged two years and older for contrast-enhanced MRI of the central nervous system (CNS) and whole body. “Visit stand 223 in exhibition hall X2, level -2, to see how our cutting-edge solutions are shaping the future of medical imaging,” the company says.
Guerbet is also hosting education-led symposiums on February 27 and 28 at 12.30-1.30pm in rooms K1 and O1. The speakers will take delegates through cases in CNS, paediatric and abdominal indications enhanced with Elucirem, sharing key insights and learnings.
“Discover our innovations, chat with our experts and explore CPD-accredited educational opportunities,” Guerbet says.
Click here to access Elucirem prescribing information.
Visit Guerbet at ECR on stand 104 – X1.
This news story has been sponsored by the companies concerned and does not represent the views or opinions of RAD Magazine. Visit our dedicated ECR conference page to find out more.
